HALOZYME THERAPEUTICS INC's ticker is and the CUSIP is 40637HAD1. A total of 64 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,916,506 | +21.0% | 2,302,000 | +21.0% | 0.00% | 0.0% |
| Q2 2023 | $1,583,415 | -1.3% | 1,902,000 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,603,576 | -19.3% | 1,902,000 | -10.4% | 0.00% | 0.0% |
| Q4 2022 | $1,987,659 | -19.2% | 2,123,000 | -26.0% | 0.00% | 0.0% |
| Q3 2022 | $2,461,000 | +81.0% | 2,870,000 | +92.4% | 0.00% | 0.0% |
| Q2 2022 | $1,360,000 | – | 1,492,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Wellesley Asset Management | 128,679,626 | $110,468,006 | 5.49% |
| CAMDEN ASSET MANAGEMENT L P /CA | 77,223,000 | $65,160,767 | 2.42% |
| Penn Mutual Asset Management | 1,555,000 | $1,312,109 | 1.23% |
| ZAZOVE ASSOCIATES LLC | 9,108,000 | $7,715,000 | 0.80% |
| DAVIDSON KEMPNER CAPITAL MANAGEMENT LP | 50,000,000 | $42,190,000 | 0.67% |
| LAFFER TENGLER INVESTMENTS, INC. | 2,399 | $2,032,823 | 0.60% |
| SHENKMAN CAPITAL MANAGEMENT INC | 9,019,000 | $7,767,672 | 0.58% |
| LINDEN ADVISORS LP | 62,930,000 | $53,329,425 | 0.55% |
| SSI INVESTMENT MANAGEMENT LLC | 4,577,000 | $3,862,074 | 0.32% |
| Sonora Investment Management Group, LLC | 4,355,000 | $3,675,060 | 0.31% |